Clinical trials: Dementia Senile
- Condition Dementia Senile
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Alzheimers Disease
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging…
- Trial name
- NCT07781345
- Testing
- No Intervention
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease
Memesto Wearable Device for Persons With Dementia
An estimated 70% of the 7.2+ million people in the U.S. with Alzheimer's Disease and Alzheimer's Disease-Related Dementias experience agitation, characterized by poorly organized and purposeless psychomotor activity that…
- Trial name
- NCT05153161
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Edgewater Safety Systems, Inc.
Alzheimer's Disease
The Feasibility of Florbetapir Quantitation in Europe
This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.
- Trial name
- NCT02107599
- Testing
- Florbetapir (18F)
- Where
- Netherlands
- Volunteers
- 96 people
- Sponsor
- Avid Radiopharmaceuticals
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Eating Disorders, Binge Eating Disorder
Optimizing a Smartphone Application for Individuals With Eating Disorders
This study will augment an existing mobile application for individuals with eating disorders by developing adaptive, tailored content targeting remediation of cognitive distortions.
- Conditions
- Eating Disorders, Binge Eating Disorder, Bulimia Nervosa
- Trial name
- NCT02503098
- Testing
- Recovery Record adaptive smartphone application, Recovery Record standard smartphone application
- Where
- 2 sites in United States
- Volunteers
- 3,340 people
- Sponsor
- Recovery Record Research
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
- Trial name
- NCT02162264
- Testing
- Donepezil Hydrochloride
- Where
- Japan
- Volunteers
- 8,662 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Alzheimer's Disease
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01689246
- Testing
- TRx0237 150 mg/day, TRx0237 250 mg/day
- Where
- 121 sites in United States, Australia and 14 more
- Volunteers
- 891 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimer Disease, Dementia
A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease
The purpose of this study is to collect and compare information regarding the treatment and outcome of patients diagnosed with Alzheimer's disease who are receiving either drug or nondrug treatment.
- Conditions
- Alzheimer Disease, Dementia, Nervous System Diseases, Mental Disorders
- Trial name
- NCT00291421
- Volunteers
- 2,360 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer´s Disease
AD01 Follow up Extension Visit
Patients who were vaccinated with AFFITOPE AD01 during AFFiRiS001 will undergo a long-term follow-up period to get more information regarding the safety profile of AFFITOPE AD01.
- Trial name
- NCT01225809
- Where
- Austria
- Volunteers
- 17 people
- Sponsor
- Affiris AG
Alzheimer's Disease
Augmenting Flortaucipir Dosimetry Estimates
This study will obtain data from urine in subjects administered flortaucipir in an Avid-sponsored study to augment the calculation of radiation dosimetry estimates.
- Trial name
- NCT02336360
- Testing
- Flortaucipir F18
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Dementia, Alzheimer Disease
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.
- Conditions
- Dementia, Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- NCT05418296
- Testing
- A novel digital health device
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- mandy
Amblyopia
Evaluation of a Smartphone Application, GoCheckKids™ as a Photo Screening Tool in a Pediatric Population
Objective: Prospective evaluation of GoCheckKids™, a smartphone application ('App') as a photo screening device in a pediatric population to detect amblyopia risk factors (ARFs) Method: Photorefraction images are captured using…
- Trial name
- NCT03119675
- Testing
- GoCheck Kids (iOS), GoCheck Kids (Windows)
- Volunteers
- 358 people
- Sponsor
- Gobiquity Mobile Health
Alzheimer Disease
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease
This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient.
- Trial name
- NCT04855955
- Testing
- Adipose-Derived Mesenchymal Stem Cells
- Sponsor
- Celltex Therapeutics Corporation
Alzheimer's Disease
Open Label Study of TRx0014 in Alzheimer's Disease
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001…
- Trial name
- NCT00684944
- Testing
- TRx0014
- Volunteers
- 111 people
- Sponsor
- TauRx Therapeutics Ltd
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Agitation
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
- Trial name
- NCT06052254
- Testing
- 12 cm2 - 2 Active DMTS Patches
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Teikoku Pharma USA, Inc.
Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD.
- Trial name
- NCT04339413
- Testing
- Gantenerumab
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Alzheimer Dementia
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients
This placebo-controlled, double blind study evaluates the treatment effects of adding a multi-pathway botanical dietary supplement (ReBuilder) to the standard treatment regimens of subjects diagnosed with mild or moderate stage…
- Trial name
- NCT03611439
- Testing
- ReBuilder
- Volunteers
- 50 people
- Sponsor
- Genescient Corporation